Celecoxib

Generic Name: Celecoxib

Brand Names: Celebrex, Elyxyb, Seglentis

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₄F_₃N_₃O_₂S

CAS Number: 169590-42-5

Unique Ingredient Identifier: JCX84Q7J1L

Background: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication: Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.

It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.

Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions: Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain

Clinical Trials

Peri-Articular-Multimodal Drug and Oral Celecoxib in Management of Postoperative Pain of Total Knee Arthroplasty

Phase 2

Completed

Conditions: Postoperative Pain
Total Knee Arthroplasty

Interventions: Drug: Multimodal Drug
Drug: epinephrine
Drug: celecoxib

First Posted Date: 2022-04-13

Last Posted Date: 2022-04-14

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 146

Registration Number: NCT05324995

Locations: 🇮🇷
Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

Phase 3

Completed

Conditions: KNEE OSTEOARTHRITIS

Interventions: Drug: X0002 Spray
Drug: Celecoxib capsules
Drug: placebo

First Posted Date: 2022-04-12

Last Posted Date: 2023-03-07

Lead Sponsor: Jiangsu XinChen-Techfields Pharma Co., LTD.

Target Recruit Count: 180

Registration Number: NCT05324163

Locations: 🇨🇳
China,Beijing, BeiJing, China

Celecoxib in Postoperative Analgesia for Radius Fracture Surgery

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Placebo
Drug: Celecoxib 100 mg

First Posted Date: 2022-03-21

Last Posted Date: 2024-02-07

Lead Sponsor: Charles University, Czech Republic

Target Recruit Count: 42

Registration Number: NCT05288374

Locations: 🇨🇿
Jiří Málek, Praha 3, Czechia
🇨🇿
Faculty Hospital Kralovske Vinohrady, Praha, Czechia

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Phase 1

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: chidamide
Drug: celecoxib

First Posted Date: 2022-03-16

Last Posted Date: 2024-12-20

Lead Sponsor: Taipei Medical University Shuang Ho Hospital

Target Recruit Count: 9

Registration Number: NCT05281276

Locations: 🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan

Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B

Phase 2

Conditions: To Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues in Nucleos(t)Ide-treated Patients With Chronic Hepatitis B

Interventions: Drug: Celecoxib
Drug: nucleos(t)ide analogue

First Posted Date: 2022-02-25

Last Posted Date: 2022-08-03

Lead Sponsor: Lai Wei

Target Recruit Count: 47

Registration Number: NCT05256823

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Bejing Tsinghua Changgung Hospital, Beijing, Bejing, China
🇨🇳
Tianjin Third Center Hospital, Tianjin, Tianjin, China

and more 1 locations

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: Ilaprazole
Drug: Naproxen
Drug: Aceclofenac
Drug: Celecoxib

First Posted Date: 2022-02-14

Last Posted Date: 2023-06-28

Lead Sponsor: Il-Yang Pharm. Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT05237297

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: PrimeC-ER 748 mg
Drug: Ciprofloxacin 750 MG
Drug: Celecoxib 200mg

First Posted Date: 2022-02-09

Last Posted Date: 2022-10-25

Lead Sponsor: NeuroSense Therapeutics Ltd.

Target Recruit Count: 12

Registration Number: NCT05232461

Locations: 🇺🇸
Novum, Fargo, North Dakota, United States

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

Phase 2

Withdrawn

Conditions: 2019-nCoV Disease
2019-nCoV Infection
COVID-19 Virus Infection
COVID-19
2019 Novel Coronavirus Disease
COVID-19 Pandemic
Coronavirus Disease 2019
SARS-CoV-2 Infection
SARS-CoV-2 Acute Respiratory Disease
COVID-19 Virus Disease

Interventions: Drug: Placebo
Drug: Famotidine
Drug: Celecoxib

First Posted Date: 2021-10-20

Last Posted Date: 2023-10-10

Lead Sponsor: Leidos Life Sciences

Registration Number: NCT05085574

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

Phase 2

Terminated

Conditions: 2019 Novel Coronavirus Infection
2019-nCoV Disease
COVID-19 Pandemic
SARS-CoV2 Infection
2019-nCoV Infection
COVID-19
Coronavirus Disease 2019
COVID-19 Virus Disease
2019 Novel Coronavirus Disease
COVID-19 Virus Infection

Interventions: Drug: Placebo
Drug: Famotidine
Drug: Celecoxib

First Posted Date: 2021-10-14

Last Posted Date: 2024-07-09

Lead Sponsor: Leidos Life Sciences

Target Recruit Count: 4

Registration Number: NCT05077969

Locations: 🇺🇸
Integrated Therapeutic Solutions USA, Inc., Dallas, Texas, United States
🇺🇸
Integrated Therapeutic Solutions USA, Inc, Dearborn, Michigan, United States
🇺🇸
Integrated Health Solutions USA, Inc., Atlanta, Georgia, United States

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

Phase 2

Active, not recruiting

Conditions: 2019-nCoV Disease
SARS-CoV-2 Infection
SARS-CoV-2 Acute Respiratory Disease
2019-nCoV Infection
Coronavirus Disease 2019
2019 Novel Coronavirus Disease
COVID-19 Virus Infection
COVID-19
2019 Novel Coronavirus Infection
COVID-19 Pandemic

Interventions: Drug: Famotidine
Other: Placebo
Drug: Celecoxib

First Posted Date: 2021-10-14

Last Posted Date: 2023-10-10

Lead Sponsor: Leidos Life Sciences

Target Recruit Count: 2000

Registration Number: NCT05077332

Locations: 🇺🇸
US02-04: Integrated Health Solutions, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy